NEW YORK (GenomeWeb News) – Agilent Technologies reported after the close of the market on Wednesday that revenues during its fiscal third quarter inched up 2 percent year over year as the company missed the average analyst estimate on the top and bottom line.

For the three months ended July 31, revenues totaled $1.72 billion, compared to $1.69 billion for the third quarter a year ago. The company fell short of the average analyst estimate of $1.79 billion.

Orders during the quarter were down 2 percent to $1.66 billion from $1.69 billion a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.